Quick-Med Technologies is Developing a Next Generation Skin Sanitizer Technology to Provide Long-Lasting Protection from MRSA
Quick-Med Technologies zu myNews hinzufügen Was ist das?
Quick-Med Technologies reports that it is developing NimbuDerm™,
an advanced skin and hand sanitizer technology that human and lab tests
show to be a unique combination of instant and long-lasting personal
antimicrobial protection. This innovation comes at a time when there’s
growing concern that many common, everyday surfaces - such as doorknobs,
desks, keyboards, and phones - are contaminated with harmful bacteria,
including potentially deadly methicillin-resistant Staphylococcus
aureus, or MRSA, and others resistant to many of today’s
antibiotics.
Currently, most hand sanitizers rely on alcohol to disinfect and
sanitize the skin. These products do an excellent job of rapidly
cleaning hands and extend hand hygiene to many situations where washing
hands simply isn’t practical. However,
sanitized hands are quickly vulnerable to recontamination from touching
additional surfaces. Unlike soap, which has some residual protection,
traditional hand sanitizers provide no ongoing protection as their
antimicrobial protection ceases as rapidly as hands dry and the
alcohol-based active ingredient evaporates.
"Quick-Med’s
NimbuDerm technology has the potential to dramatically change the
hand-hygiene paradigm by combining the immediate disinfection power of
an instant sanitizer with the long-lasting antimicrobial persistence of
an advanced bio-active polymer,” declared Dr.
Gerald M. Olderman, Vice President of R&D and leader of the company’s
scientific team. "With many infections being
transferred via hand contact, we believe NimbuDerm’s
third-generation technology could bring a new level of hand-hygiene
assurance to consumers and healthcare professionals alike”
he observed.
Laboratory tests demonstrate that NimbuDerm’s
unique antimicrobial polymer properties will kill more than 99.99% of
disease causing germs, including the lethal strain of MRSA. Human use
tests show that NimbuDerm also provides the same high level of
continuing antimicrobial protection for 6 hours after each application
without wearing off or losing its effectiveness. Poor hand hygiene is
considered to be a major contributor to the increase in MRSA infections.
MRSA, which has been identified in hospitals for 4 decades, is now
increasingly found in schools, gymnasiums, and offices, and on common "touch
surfaces” such as keyboards, door knobs,
desktops, telephones and shopping cart handles. According to the Centers
for Disease Control and Prevention, in 2005 MRSA was responsible for an
estimated 94,000 life-threatening infections and 18,650 deaths in the
United States. MRSA is becoming increasingly problematic, not only in
acute care settings, but also in long-term care facilities and the
community. "We are on the verge of losing control of the situation,
particularly in the hospitals," observed Dr. Chip Chambers, Chief of
Infectious Disease at San Francisco General Hospital in a January 20, 2008 feature article in the San Francisco Chronicle.
The NimbuDerm technology contains no triclosan, the active ingredient
found in many antibacterial soaps and the subject of considerable
current controversy. Studies have shown that large polymers such as
NimbuDerm will not generate bacterial resistance. NimbuDerm technology
can be incorporated into various formulations, and is compatible with
common additives such as emollients (to help keep skin soft and
hydrated), therapeutic nutrients, and other active ingredients.
NimbuDerm technology is not yet available commercially. Quick-Med
Technologies is seeking a partner to help bring this important and
needed technology to the market in developing final product
formulations, preparing marketing plans, and importantly, taking the
necessary steps to satisfy applicable FDA and other countries’
regulatory requirements.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is
developing broad-based technologies for the healthcare and consumer
markets. The Company's two core product groups under development are (1)
NIMBUS®, a
technology employing advanced polymers that can be used in a wide range
of applications from advanced wound care to industrial and consumer
products; and (2) MultiStat™ family of
advanced patented methods and compounds, shown to be effective in key
skin care therapy applications for cosmetic, military, and medical
markets. For more information, see: www.quickmedtech.com. © 2008 Quick-Med Technologies, Inc. All
rights reserved. NIMBUS®
and MultiStat™ are trademarks of Quick-Med
Technologies, Inc. All other trademarks are the property of their
respective owners.
Safe Harbor Forward-Looking Statements Certain statements contained in this press release may be deemed to
be forward-looking statements under federal securities laws, and
Quick-Med Technologies, Inc. intends that such forward looking
statements be subject to the safe harbor created thereby. Quick-Med
Technologies, Inc. does not undertake an obligation to publicly update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.